- Home
- PSMT vs MIRM Comparison
PSMT vs MIRM Comparison
Compare PSMT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSMT | MIRM |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.7B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSMT | MIRM |
|---|---|---|
| Price | $174.13 | $93.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $119.85 |
| AVG Volume (30 Days) | 179.0K | ★ 899.6K |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | 5.47 | ★ 74.59 |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $4,066,093,000.00 | $19,138,000.00 |
| Revenue This Year | $12.29 | $26.22 |
| Revenue Next Year | $10.70 | $22.04 |
| P/E Ratio | $59.47 | ★ N/A |
| Revenue Growth | ★ 12.33 | N/A |
| 52 Week Low | $99.98 | $45.37 |
| 52 Week High | $174.93 | $114.99 |
Technical Indicators
Market Signals| Indicator | PSMT | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 66.53 | 42.38 |
| Support Level | $153.14 | $87.26 |
| Resistance Level | N/A | $98.03 |
| Average True Range (ATR) | 4.96 | 4.55 |
| MACD | 0.55 | -1.14 |
| Stochastic Oscillator | 75.96 | 22.14 |
Price Performance
Historical ComparisonAbout PSMT PriceSmart Inc.
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.